Preferred Label : fruquintinib;

Details


Keyword's position in hierarchy(ies) : arborescence

Main resources

You can consult :


https://www.ema.europa.eu/en/medicines/human/EPAR/fruzaqla
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
fruquintinib
fruquintinib
administration, oral
drug approval
europe
VEGFR Tyrosine Kinase Inhibitor
fruquintinib
VEGFR Tyrosine Kinase Inhibitor
receptors, vascular endothelial growth factor
Tyrosine Kinase Inhibitors
Tyrosine Kinase Inhibitors
risk management
product surveillance, postmarketing
antineoplastic agents
antineoplastic agents
neoplasm metastasis
colorectal neoplasms
Metastatic Colorectal Carcinoma
Refractory Colorectal Carcinoma
adult
drug interactions
aged
pregnancy
breast feeding
drug evaluation, preclinical

---
https://ansm.sante.fr/tableau-acces-derogatoire/fruzaqla
2024
false
false
false
France
French
administration, oral
fruquintinib
antineoplastic agents
fruquintinib
VEGFR Tyrosine Kinase Inhibitor
summary of product characteristics
drug information
colorectal neoplasms
neoplasm metastasis

---
https://www.has-sante.fr/jcms/p_3553066/fr/fruzaqla-fruquintinib-cancer-colorectal-metastatique
2024
false
false
false
France
neoplasm metastasis
insurance, health, reimbursement
treatment outcome
fruquintinib
Tyrosine Kinase Inhibitors
Metastatic Colorectal Carcinoma
adult
administration, oral
evaluation of the transparency committee
colorectal neoplasms
fruquintinib

---
Nous contacter.
04/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.